Day One Biopharmaceuticals (NASDAQ:DAWN) Now Covered by TD Cowen

TD Cowen started coverage on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $34.00 price target on the stock.

DAWN has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. JPMorgan Chase & Co. boosted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Piper Sandler increased their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $10.59 on Tuesday. Day One Biopharmaceuticals has a one year low of $5.64 and a one year high of $13.53. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.97 and a beta of -1.27. The company’s 50-day simple moving average is $9.09 and its two-hundred day simple moving average is $7.74.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. The firm had revenue of $39.80 million during the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company’s revenue was down 57.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 EPS. Equities analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,062 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $8.91, for a total transaction of $36,192.42. Following the sale, the chief financial officer owned 294,715 shares of the company’s stock, valued at approximately $2,625,910.65. The trade was a 1.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lauren Merendino sold 3,726 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $8.91, for a total transaction of $33,198.66. Following the transaction, the insider owned 50,809 shares in the company, valued at $452,708.19. The trade was a 6.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 28,001 shares of company stock worth $249,489 in the last three months. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in DAWN. Schroder Investment Management Group acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth about $1,171,000. Geode Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals by 11.2% in the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock worth $11,132,000 after purchasing an additional 171,964 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its holdings in shares of Day One Biopharmaceuticals by 71.7% during the second quarter. Dynamic Technology Lab Private Ltd now owns 83,223 shares of the company’s stock worth $541,000 after purchasing an additional 34,766 shares during the period. Rhumbline Advisers boosted its position in Day One Biopharmaceuticals by 8.3% in the first quarter. Rhumbline Advisers now owns 81,844 shares of the company’s stock valued at $649,000 after buying an additional 6,291 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its position in Day One Biopharmaceuticals by 137.0% in the second quarter. Virtus Investment Advisers LLC now owns 66,427 shares of the company’s stock valued at $432,000 after buying an additional 38,397 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Key Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Strong commercial results and outlook — Management updated revenue guidance and highlighted robust OJEMDA sales and a stronger 2026 outlook, which underpinned the recent rally. A Look At Day One Biopharmaceuticals Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates
• Positive Sentiment: Analyst initiation with a high price target — TD Cowen started coverage with a Buy and a $34 target, signaling strong upside from current levels and providing institutional validation for the story. Benzinga Coverage Note
• Neutral Sentiment: Investor presentation transcript available — Day One presented at the J.P. Morgan Healthcare Conference (transcript published), offering more color on commercial execution and pipeline but without new headline data. Useful for investors doing due diligence. J.P. Morgan Presentation Transcript
• Neutral Sentiment: Earlier surge flagged as potentially unsustainable — Coverage noting a 26.7% intraday jump and above-average volume cautions that recent earnings-estimate revision trends don’t clearly support further strength, suggesting momentum may be fragile. Zacks Note on the Surge
• Negative Sentiment: High short interest adds downside pressure — As of Dec. 31, short interest rose to ~11.18M shares (about 11.6% of shares outstanding) with a short-interest ratio ~4.5 days; that level can amplify volatility and fuel both short-covering spikes and selling pressure when momentum shifts. (Market data summary)
• Negative Sentiment: Fast profit-taking after the guidance-driven rally — Multiple outlets reported the stock surged on the stronger 2025/2026 outlook; rapid gains on heavy volume often trigger pullbacks and trimming by momentum traders, contributing to today’s decline. Investing.com: Stock Soars After Forecast MSN: Shares Surge on Outlook

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.